It is important that patients’ broader health needs are addressed
Rheumatoid arthritis and seronegative spondyloarthropathies are the most common types of inflammatory arthritis. They cause pain, joint damage and progressive functional loss, which limit participation in life and constitute a significant disease burden.1,2 Over the past decades, great advances in management, with the availability of corticosteroids, synthetic disease-modifying antirheumatic drugs (DMARDs) and biological DMARDs, have significantly improved the disease control and outcomes. The guidelines, whose algorithms focus on drug prescription to achieve remission of disease,3,4 support everyday treatment. However, while they provide direction for the use of DMARDs, they do not consider the patients’ broader health needs.
Publication of your online response is subject to the Medical Journal of Australia's editorial discretion. You will be notified by email within five working days should your response be accepted.